NCT02574260View on ClinicalTrials.gov

An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)

PHASE2CompletedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Melanoma

Interventions

BIOLOGICAL

Talimogene Laherparepvec

Administered by intratumoral injection.

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Covance

INDUSTRY

lead

BioVex Limited

INDUSTRY